CClinicalTrials.gg
Sign In
Not yet recruitingNCT07544719Updated Apr 22, 2026

Systemic Immun Inflamation Score Corelation in Postoperative Patients Prognosis

An observational study in Geriatric Anesthesia and Postop Adult ICU Patients, sponsored by Malatya Egitim Ve Arastirma Hastanesi. Not yet recruiting. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Malatya Egitim Ve Arastirma Hastanesi · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
65 Years and older
Sex
All
01

Study summary

The Systemic Immuno-Inflammation Index (SII) is a ratio derived from complete blood count parameters (neutrophils, lymphocytes, platelets) and is a non-invasive and easily calculable biomarker. The SIPI effectively reflects both local and systemic inflammatory responses in the human body. It has been used to predict and evaluate the prognosis of various solid tumors such as gastric cancer, non-small cell lung cancer, and colorectal cancer. Furthermore, the SIPI has been shown to have significant prognostic value in cardiovascular and cerebrovascular diseases. In this study, the SIPI will be calculated using laboratory data at the time of admission to the intensive care unit, and the relationship between the obtained values and the 30-day mortality status of the patients will be analyzed.

02

Conditions studied

  • Geriatric Anesthesia
  • Postop Adult ICU Patients
03

In context

Lead sponsor

Malatya Egitim Ve Arastirma Hastanesi is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

65 years of age or older postoperative patients

Inclusion criteria

  • The patient must be 65 years of age or older (in the geriatric age group),
  • Admitted to the intensive care unit after elective or emergency surgery
  • Have access to complete blood count (hemogram) data (neutrophils, lymphocytes, platelets) during their stay in the intensive care unit
  • Be able to undergo 30-day mortality monitoring from the date of admission to the intensive care unit
  • Have provided informed consent from the patient or their legal representative.

Exclusion criteria

Exclusion Criteria:

  • Patients under 65 years of age
  • Patients admitted to the intensive care unit for non-surgical reasons (e.g., trauma, medical intensive care indications)
  • Patients with deficient neutrophil, lymphocyte, or platelet counts upon admission to the intensive care unit
  • Patients with a history of malignancy, hematological disease, or immunosuppressive therapy
  • Terminally ill palliative patients
  • Patients who refuse informed consent.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Measuring the Systemic Immune-Inflammation Index (SII) in postoperative patients to see the parameter's predictibility of 30-day mortality

    In geriatric patients admitted to the intensive care unit after surgery, the Systemic Immune-Inflammation Index (SII) is a significant biomarker for predicting 30-day mortality.

    Time frame: Postoperative day 1

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, Chen CQ, He YL, Cai SR. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017 Sep 14;23(34):6261-6272. doi: 10.3748/wjg.v23.i34.6261. PubMed 28974892 ↗
  • Zeng QY, Qin Y, Shi Y, Mu XY, Huang SJ, Yang YH, Liu SM, An ZM, Li SQ. Systemic immune-inflammation index and all-cause and cause-specific mortality in sarcopenia: a study from National Health and Nutrition Examination Survey 1999-2018. Front Immunol. 2024 Apr 4;15:1376544. doi: 10.3389/fimmu.2024.1376544. eCollection 2024. PubMed 38638440 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07544719
Lead sponsor
Malatya Egitim Ve Arastirma Hastanesi
Responsible party
Leman Acun Delen (Associate Professor, Malatya Egitim Ve Arastirma Hastanesi) — Principal investigator
First posted
Apr 22, 2026
Start date
Jun 15, 2026 (estimated)
Primary completion
Jul 15, 2026 (estimated)
Completion
Jul 30, 2026 (estimated)
Last update
Apr 22, 2026

Study contacts

Ayşe Yılkınç Tekirdaş
Contact
ylknc.ys.44@hotmail.com
+905395721741

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Malatya Egitim Ve Arastirma Hastanesi

Start the discussion